Search the Newsreel

PuraPharm Sets Board Meeting to Approve Interim Results and Consider Dividend

Research Analysts Issue Forecasts for BCRX Q4 Earnings

Sirenia Capital (TNXP) discloses 4.9% Tonix Pharmaceuticals stake including warrants

Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 4.9% in Tonix Pharmaceuticals Holding Corp., which includes 814,801 shares of common stock. This stake comprises 615,025 shares issuable upon the exercise of warrants. The ownership percentage is calculated based on …

Analyst Estimates: Here's What Brokers Think Of BridgeBio Pharma, Inc. (NASDAQ:BBIO) After Its Second-Quarter Report

This article analyzes what brokers think of BridgeBio Pharma, Inc. (NASDAQ:BBIO) following its second-quarter report. It would likely detail analyst ratings, price targets, and any changes in sentiment post-earnings, providing insights into the company's financial performance and future outlook from an investment perspective.

Sirenia Capital (TRAW) discloses warrant-based stake capped at 9.9% ownership

Sirenia Capital Management LP and Alex Silverstein have disclosed a beneficial ownership stake in Traws Pharma, Inc. (TRAW) through warrants. The Sirenia-managed funds hold warrants exercisable for 6,565,474 shares of common stock, but their actual beneficial ownership is capped at 9.9% due to a …

GTBP: Q2 2026 net loss narrowed to $4.5M as clinical programs advance and cash runway extends to Q4 2026

GT Biopharma (GTBP) reported a narrowed net loss of $4.5 million in Q2 2026, a significant improvement from $30.2 million year-over-year, attributed to the absence of a prior non-recurring liability. The company is advancing two TriKE® candidates in Phase 1 trials, with updates anticipated …

Vertex to acquire Crinetics after HSR clearance; closing expected early Sept

Crinetics Pharmaceuticals announced that it has received HSR clearance for its merger with Vertex. The HSR waiting period expired on August 12, 2026, and antitrust approvals have also been secured in Austria, Germany, and Australia. The merger's closing is targeted for early September 2026, …

Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript

Crinetics Pharmaceuticals (CRNX) advances Vertex merger after key antitrust milestones

Crinetics Pharmaceuticals announced significant progress in its planned acquisition by Vertex Pharmaceuticals, with the Hart-Scott-Rodino waiting period expiring and antitrust approvals secured in Austria, Germany, and Australia. The merger's completion hinges on Crinetics shareholder approval at a meeting on August 28, 2026, with an …

Sutro Biopharma Q3 EPS Forecast Reduced by HC Wainwright

Zacks Research Has Optimistic Outlook of WST Q3 Earnings

Zacks Research has updated its Q3 2026 earnings per share (EPS) estimate for West Pharmaceutical Services (NYSE: WST) to $2.14, maintaining a "Hold" rating. This optimistic outlook follows West Pharmaceutical's recent strong quarterly performance, where the company exceeded earnings and revenue expectations and raised …

What is HC Wainwright's Forecast for MIST Q3 Earnings?

No approved treatment for Peeling Skin Syndrome as Quoin plans Phase 2/3 study

Quoin Pharmaceuticals reported key pipeline milestones and its Q2 2026 financial results. The FDA granted conditional approval for QYLEKI™ as the proposed brand name for QRX003, intended for Netherton Syndrome, and cleared the first-ever IND for Peeling Skin Syndrome, enabling a Phase 2/3 study …

Deep Track Capital (XFOR) discloses 8.33% X4 Pharmaceuticals stake with capped warrants

Deep Track Capital and its affiliates have reported a beneficial ownership of 8.33% in X4 Pharmaceuticals (XFOR), totaling 8,040,894 shares with shared voting and dispositive power. This stake includes 2,162,137 Pre-Funded Warrants, which are subject to a 9.99% "Maximum Percentage" ownership cap, limiting their …

Ovarian cancer drug trial completes enrollment; PMV plans 2027 filing

PMV Pharmaceuticals reported Q2 2026 financial results and clinical progress for rezatapopt, including the completion of enrollment for the primary analysis in its Phase 2 PYNNACLE trial for platinum-resistant/refractory ovarian cancer. The company plans to submit a New Drug Application (NDA) for accelerated approval …

PMVP: Net loss narrowed, but liquidity concerns persist as rezatapopt advances toward NDA submission

PMV Pharmaceuticals (PMVP) reported a narrowed net loss of $18.1 million for Q2 2026, with $79.4 million in cash and equivalents. Despite progress with rezatapopt towards an NDA submission in early 2027, the company faces substantial doubt about its ability to continue operations without …

PMV Pharmaceuticals (PMVP) flags going-concern risk as rezatapopt advances toward NDA

PMV Pharmaceuticals reported a Q2 2026 net loss of $18.1 million and a first-half loss of $36.1 million, disclosing substantial doubt about its ability to continue as a going concern, as current cash resources are only expected to fund operations through Q2 2027. Despite …

Form 8K Pmv Pharmaceuticals Inc For: 14 August By Investing.com

This article from Investing.com announces the filing of a Form 8K by PMV Pharmaceuticals Inc. on August 14th. The brief piece includes the company's stock symbol PMVP and its real-time performance. The core content is minimal, serving primarily as a notification of the regulatory …

Is Lantern Pharma Inc (LTRN) Facing Increased Losses After Q2 Earnings Miss? GF Score: 34/100

GT Biopharma (GTBP) cuts net loss but flags going concern and Nasdaq risk

Wedge Capital Management L L P NC Acquires Shares of 380,801 BioCryst Pharmaceuticals, Inc. $BCRX

Wedge Capital Management L.L.P. NC recently purchased 380,801 shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for approximately $3.8 million, now holding 0.15% of the company. Institutional investors collectively own 85.88% of the biotechnology firm. BioCryst Pharmaceuticals reported strong quarterly earnings, beating analyst estimates with $0.30 …

GT Biopharma Reports Second Quarter 2026 Financial Results

GT Biopharma announced its second quarter 2026 financial results, highlighting ongoing Phase 1 trials for two TriKE® candidates, GTB-3650 and GTB-5550, with updates expected in the second half of 2026. The company reported a cash balance of $5.1 million, sufficient to fund operations through …

Renaissance Technologies LLC Takes $1.19 Million Position in Corvus Pharmaceuticals, Inc. $CRVS

Renaissance Technologies LLC has acquired a new stake worth $1.19 million in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), indicating growing institutional interest, with hedge funds now owning 46.64% of the company. Despite positive analyst sentiment and a "Moderate Buy" rating, recent earnings missed estimates, and HC …

Driehaus Capital discloses 6.96% Cue Biopharma (CUE) holding in Schedule 13G

Driehaus Capital Management LLC has disclosed a 6.96% beneficial ownership stake in Cue Biopharma, Inc. (CUE), amounting to 292,144 shares. This holding is reported on a Schedule 13G filing, indicating a passive investment. The shares are held in fully discretionary accounts for investment advisory …

West Pharmaceutical Services (NYSE:WST) Rating Lowered to Hold at Zacks Research

Zacks Research downgraded West Pharmaceutical Services (NYSE:WST) from "strong buy" to "hold" despite the company reporting strong quarterly results, exceeding EPS and revenue estimates. The broader analyst consensus remains a "Moderate Buy" with an average price target of $368.08. West Pharmaceutical Services posted Q2 …

NRXP Q2'26 Earnings: EPS estimate is (0.11) USD

NRX Pharmaceuticals, Inc. (NRXP) is scheduled to announce its Q2'26 earnings on August 17th. The company anticipates a revenue of $1.33 million and an earnings per share (EPS) of ($0.11) for the quarter. This article provides a historical comparison of reported and estimated revenue …

Zentalis adds USD 80.5m as azenosertib nears pivotal test

Zentalis Pharmaceuticals has raised approximately USD 80.5 million through an equity offering to fund the late-stage development and pre-commercial activities for its oral WEE1 inhibitor, azenosertib. The drug is being evaluated for Cyclin E1-positive platinum-resistant ovarian cancer, with Phase II data expected by year-end …

CTXR Q3'26 Earnings: EPS estimate is (0.36) USD

Citius Pharmaceuticals, Inc. (CTXR) is scheduled to release its Q3'26 earnings on August 17, 2026, with the disclosure expected at 8:00 AM ET (12:00 PM UTC). The company anticipates a Q3'26 revenue of 5.46 million USD and an EPS of (0.36) USD. This article …

Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ligand Pharmaceuticals stock has surged over the past five years, yet the valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic value estimate …

Lantern Pharma Inc. Q2 2026: Net income $(7.07M), EPS $(0.57) — 10-Q Summary

Lantern Pharma Inc. reported a consolidated net loss of $(7.07M) and an EPS of $(0.57) for Q2 2026, marking a significant increase in losses compared to the previous year, with no revenue reported. Despite the financial losses, the company continued to advance its clinical …

BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base

BridgeBio Pharma, Inc. announced the pricing of an oversubscribed secondary offering of 5,000,000 shares of its common stock by KKR Genetic Disorder L.P. The company itself is not selling shares and will not receive any proceeds from the offering. This transaction aims to further …

KKR to Sell 5M BridgeBio Shares; Company Receives No Proceeds

BridgeBio Pharma announced the pricing of a secondary offering of 5,000,000 shares of its common stock by existing shareholder KKR Genetic Disorder L.P. BridgeBio will not issue any shares or receive any proceeds from this transaction, which is expected to close on August 17, …

BridgeBio Pharma (BBIO) holders to resell 5M shares in $390M offering

BridgeBio Pharma is facilitating a secondary offering where a KKR-affiliated selling stockholder will sell 5,000,000 shares of common stock at $78.00 per share, totaling $390 million. BridgeBio Pharma will not receive any proceeds from this transaction, as all net proceeds will go to the …

VOR|Vor Biopharma Inc|Price:23.260|Chg%:+0.920

Quantum BioPharma Says Cash Could Fund Plans to Oct. 2027

Acumen's Q2 Loss Narrows; Topline Phase 2 Data For Alzheimer's Drug Sabirnetug In Late '26

(RTTNews) - Acumen Pharmaceuticals Inc. (ABOS), a clinical-stage biopharmaceutical company, on Wednesday announced second quarter financial results and noted a lower net loss owing to reduced research and development (R&D) expenses. The company is engaged in developing novel therapeutics targeting toxic soluble amyloid beta …